PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-4.83%
Revenue decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate if market share loss is temporary.
-4.85%
Cost reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive advantage potential.
-4.74%
Gross profit decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
0.10%
Margin change of 0.10% versus flat Medical - Pharmaceuticals margins. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
37.60%
Other expenses change of 37.60% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
2.77%
Operating expenses growth near Medical - Pharmaceuticals median of 2.82%. Charlie Munger would verify industry norms.
-3.67%
Total costs reduction while Medical - Pharmaceuticals median is 2.75%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
36.52%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 3.78%. Jim Chanos would check for overinvestment.
-22.29%
EBITDA decline while Medical - Pharmaceuticals median is -0.02%. Seth Klarman would investigate causes.
-18.35%
EBITDA margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-25.27%
Operating income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-21.48%
Operating margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
139.58%
Other expenses change of 139.58% versus flat Medical - Pharmaceuticals. Walter Schloss would verify control.
-11.61%
Pre-tax income decline while Medical - Pharmaceuticals median is -1.87%. Seth Klarman would investigate causes.
-7.13%
Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-11.29%
Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-11.81%
Net income decline while Medical - Pharmaceuticals median is -0.71%. Seth Klarman would investigate causes.
-7.34%
Net margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-11.81%
EPS decline while Medical - Pharmaceuticals median is -0.07%. Seth Klarman would investigate causes.
-11.81%
Diluted EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate strategy.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate strategy.